latest news stock values companies glp-1 obesity cardiometabolic The rate in the US fell in 2023 as GLP-1s go mainstream GLP-1 Market Trends and Global

Back Trapp, S, Brierley, DI (29 July 2021) 'Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment' British Journal of Pharmacology

Advocacy groups and grieving parents continue to call for stronger safeguards to prevent what they describe as a digital drug market targeting young users

Adderall is approved for people ages 3 years and older, and Adderall XR is for people ages 6 years and older

In the second trial, SURPASS-2, tirzepatide administered at doses of 5 mg, 10 mg, or 15 mg showed superior efficacy compared to semaglutide (1 mg) in reducing body weight and HbA1c levels over 40 weeks in patients with T2DM inadequately controlled with metformin [66]